Blue Horseshoe Stocks: Kicking Off the Short Week

INSYS Therapeutics, Inc. INSY

This morning we kick off the holiday shortened week, during a time of year that typically sees subdued activity for the markets as a whole, as people spend time with their families, and stay busy with holiday festivities.

We still strive to identify possible opportunities even in this environment, and the first thing to hit our scanner this morning was INSY. INSYS Therapeutics recently initiated Phase II trials of its synthetic Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy.

The FDA, we’re learning today, has also granted Fast Track status to INSY for the ‘drug’ for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder. (View PR)

The stock registered its 52-week lows at the beginning of last month, and has been in a general uptrend since, but we’ll be looking for further bullish activity on the heels of this FDA news, both on the stock chart, and in the options chain as a secondary idea. For that, we’ll look to the INSY 01/19 $8 & $9 Calls for opportunities.

DelMar Pharmaceuticals, Inc. DMPI

Speaking of FDA Fast Track designations, we’re looking to DMPI this morning as well, which was granted the status by the FDA for its lead-product cancer treatment, VAL-083.

The chart itself was already set up as a possible bottom play, and despite gapping up considerably on this morning’s news, there is still room to the upside, including a sizable gap that’s been left on the chart since this past spring, the eventual filling of which would spell gains of more than 100% from the current PPS.

Extended Watchlist:

Blue Horseshoe Stocks: Updates, Bottom-Plays & More

Aeterna Zentaris, Inc. AEZS

We flagged AEZS on Wednesday’s morning, and saw rip its way to nearly a 90% gain. Then yesterday morning, we took note of the heavy volume and kept the stock on our radar.

It didn’t quite match the degree of the previous session’s move, but still followed it up with a solid performance, running from 2.55 to 3.29 on the day. That’s an intraday spike of 29% and a two-day upswing of 122% over our observed low of 1.48,  while volume was massive once again. We’ll be looking for AEZS to possibly continue its multi-day run, and would want to see maintain support at or above Wednesday’s closing price of 2.34 on any pullbacks, in order to remain interested.

ImmunoCellular Therapeutics, Ltd. IMUC

We want to radar IMUC as a bottom-watch play this morning. We noticed the stock had fallen to a new annual low yesterday, following the pricing of a public offering earlier this week, that is expected to be executed today.

We’re always on the lookout for battered stocks that could become rebound play candidates, and we’re always looking for charts with gaps to the upside and IMUC currently checks both of those boxes.

Extended Watchlist:

Blue Horseshoe Stocks: AEZS Recap & More

Aeterna Zentaris, Inc. AEZS

It had been quite some time since the last time we mentioned AEZS in one of our reports, but were prompted to do so yesterday, after noticing some unusual premarket activity on our routine morning scan.

It’s certainly a good thing that we did, because the stock became our number one play of the day with an outstanding performance. It also happened to be the NASDAQ’s top gainer of the day. From an early low of 1.48 the stock shot up to a high of 2.80 shortly after 1:30, marking a single-session rip of 89%

The big move came on volume exceeding the monthly average by roughly 40 times, and the stock managed to hold well over half of its gains into the close, so we’ll be sure to leave AEZS on our radar as we head into the end of the week.

Marijuana Company of America, Inc. MCOA

Another point of focus for us yesterday was MCOA, which we signaled the previous morning, and subsequently witnessed a 38% (.02685-.037) upswing. We were mentioning that, along with the fact that an interesting PR had hit newswires which we felt could set the table for further gains, and we were correct in our assumption.

Perhaps also riding the wave of invigoration that has flowed back into the cannabis space as a whole over the past few sessions, MCOA continued its ascent, trading in a range from .0361-.0467 on the day. That was good for an intraday move of 29% and extended our two-session observed range on the stock to a respectable 74%

Sears Holdings Corp. SHLD – Options Idea

We’ve had some good fortune in the past with SHLD, and more specifically, its options chain. This morning, we’re spotting another possible opportunity on that front. The company will now be selling Kenmore appliances via, and as a result, the stock is gapping up over ten percent in premarket trading this morning.

To take advantage of the commotion, we’ll have our eye on the SHLD Weekly $9-10 Calls.

Extended Watchlist:

Blue Horseshoe Stocks: Options Success & More

Options Success

Netflix, Inc. NFLX – Options  -We signaled a range of options contracts on NFLX in yesterday’s premarket report, citing the earnings beat of the previous afternoon. We specifically mentioned that we were looking out for a dip-and-rip formation on the chart and the stock produced a classic example of such. NFLX’s big day, which ultimately facilitated those multi-bag profit opportunities, was fueled by an impressive 5 million new subscribers to the Netflix streaming service.

Right out of the gate, it dipped briefly to the high $175 area before going on an hours-long bullish push to the upper $184′s. That activity led to some really nice gains in our highlighted options, the NFLX Weekly $172.50-180 Calls:

$172.50 Calls – Range: 3.80-12.75 – Max Gain: 236%
$175 Calls – Range: 2.50-10.50 – Max Gain: 320%
$177.50 Calls – Range: 1.40-8.30– Max Gain: 493%
$180 Calls – Range: .85-6.42 – Max Gain: 655%


Nutanix, Inc. NTNX – We also want to circle back to recap the moves made by an options idea we included in Friday morning’s report. NTNX continued to climb yesterday, and so the NTNX 7/21 $20-25 Calls we signaled have turned up some really nice moves.

$20 Calls – Range: 1.65-3.90 – Max Gain: 136%
$22.50 Calls – Range: .40-1.56 – Max Gain: 290%
$25 Calls – Range: .05-.28 – Max Gain: 460%

Yesterday’s Movers

We also had a number of the stocks that we highlighted in yesterday’s report yield chances for solid gains, and of them gave us a reason to look out for further moves:

Caprico Therapeutics, Inc. CAPR - The biggest gainer of the day from our mentions and on the NASDAQ itself, CAPR traded in a range from a low of .901, on up to a high of 1.62. That worked out to an 80% rip, and it came on an incredible 291X the monthly average volume.

The huge session was catalyzed by the announcement that the FDA has granted Rare Pediatric Disease Designation to CAP-1002, Capricor’s development candidate for the treatment of Duchenne muscular dystrophy. (>>View PR)

Marijuana Company of America, Inc. MCOA - There was a nice move in MCOA as the stock traded up 38% from .02685-.037 on close to five times its monthly average volume, and the table may be set for a continuation of the trend with a new PR hitting the wires this morning.

The company is reporting that it has received the first round of funding for a joint venture to construct a 30,000 sq. ft. greenhouse grow facility in Oroville, Washington. Once completed, the greenhouse facility will accommodate a cannabis production and processing tenant with a Tier 3, I-502 license… (>>View PR)

Novavax Inc. NVAX - This one recorded a very respectable gain on the day, running steadily from 1.17 up to 1.53, a 31% upswing. More importantly, the stock maintained the vast majority of its daily advance into the close, so we’ll want to continue to track NVAX as well.

Extended Watchlist:

Blue Horseshoe Stocks: News Plays & Special Reminder

Aeterna Zentaris, Inc. AEZS

AEZS is gapping up this morning on the heels of some news. It’s been quite a few months since we last mentioned this stock. That was back in the fall, and we subsequently witnessed quite a surge from the stock after that.

Since then, so far in 2017 the stock has come down to record new annual lows, and recently has been making incremental increases off of that bottom. In light of today’s news, described below, we think it’s a good time to put AEZS back on a more intensive watch.

The company announced this morning, following a comprehensive review Phase 3 clinical data on Macrilen™ for the evaluation of growth hormone deficiency, that Macrilen™ demonstrated performance supportive of achieving registration with the FDA. The FDA has agreed to consider the Company’s conclusions during a Type A meeting, which is currently being scheduled. (>>View PR)

Zosano Pharma Corp. ZSAN

Speaking of fresh news plays, we also want to highlight the announcement coming from ZSAN this morning that presently has the stock gapping up in the premarket to the tune of 50%

This morning ZSAN reported that in its ZOTRIP pivotal efficacy study, the company’s M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints. It certainly explains the premarket hoopla, and warrants our observation as we kick off a new trading week.

The chart also has some attractive features which we’ve pointed out on the snapshot below:


To wrap things up this morning, we want to leave our readers with a quick heads up on a big Tuesday coming up. We’ve got a special report coming out tomorrow prior to the opening bell. It could represent quite an opportunity, so tomorrow is definitely not the day to miss out on our premarket report!

Be sure to stay locked onto your email inboxes or tomorrow between 9:00 to 9:15AM, and lean on those refresh buttons!

Extended Watchlist: